Sign in
ERNAW Stock Price, Chart, Stats & News
Ernexa Therapeutics Inc. Warrants
Save
Ernexa Therapeutics Inc. Warrants (ERNAW) does not currently pay a dividend.
559,925
Market cap
–
Current P/E
–
Forward P/E
ERNAW chart
1M
3M
1Y
5Y
Loading chart...
About
Operating in the preclinical phase, Ernexa Therapeutics Inc. is dedicated to advancing therapies based on induced mesenchymal stem cells (iMSC) to combat both solid tumors and autoimmune conditions. Its primary therapeutic, ERNA-101, is an allogeneic iMSC specifically formulated to secrete pro-inflammatory cytokines like IL-7 and IL-15 for the treatment of ovarian cancer. Complementing this, ERNA-102 is another iMSC designed to deliver the anti-inflammatory cytokine IL-10, targeting rheumatoid arthritis.
Similar securities
Based on sector and market capitalization
Report issue